[中图分类号]F841[文献标识码]A[文章编号]1004-3306(2023)06-0109-19 DOI:10.13497/j.cnki.is.2023.06.008
资源价格:30积分
[摘 要]美国的药品价格很高,长期以来对美国的通货膨胀产生了拉抬作用,并越发成为民生负担。2022年8月,美国《通货膨胀削减法案》实施,历史性地赋予了美国联邦医保部门对药品价格进行控制的多项权力。本文按照政策措施开始实施的时间顺序,依次分析美国医保部门正在进行的四项控制药品价格的工作——提高仿制生物药的医保支付标准、给参保患者对胰岛素药品的每月自付费用“封顶”、让制药企业将药品价格增长超出同期通货膨胀的部分向医保部门退款、以及与制药企业就药品价格进行谈判。这四项改革措施在控制药价上形成了合力。然后,简要分析了美国商业保险受到的影响。最后,提炼出这四项改革措施的特点,希望为我国相关领域的决策提供参考信息。
[关键词]健康保险;生物药;仿制药;价格谈判;药品福利管理
[基金项目]国家社会科学基金年度项目(22BGL062)。
[作者简介]王向楠,中国社会科学院金融研究所副研究员、中国社会科学院保险与经济发展研究中心副主任。
The US Medical Insurance′s Control on Drug Prices:An Analysis of the “Inflation Reduction Act”
WANG Xiang-nan
Abstract:The drug prices in the United States are exorbitant,which has contributed to inflation over the long term and has increasingly become a burden on the livelihoods of its citizens.In August 2022,the US “Inflation Reduction Act” was implemented,which historically granted the federal medical insurance department(the Centers for Medicare and Medicaid Services,CMS) the authority to control drug prices.In chronological order,the paper analyzes the four initiatives implemented by the CMS to control drug prices:raising the payment benchmark for biosimilars to promote market competition,capping monthly out-of-pocket costs for insulin drugs for insured patients,requiring pharmaceutical companies to refund the portion of drug price increases that exceed the inflation rate,and negotiating drug prices with pharmaceutical companies.These four reform measures,regardless of whether they are comprehensive or precise,whether they focus on pre-or post-intervention,and whether they are direct or indirect,have worked together to control drug prices to some extent.Then,the paper briefly analyzes its impact on US commercial health insurance.Finally,it distills common characteristics from these four reform measures,aiming to provide reference information for decision-makers in related fields in China.At the same time,it summarizes the experiences from China′s medical insurance bureau′s drug price control measures for the consideration of the United States.
Key words:health insurance;biologic drug;generic drug;price negotiation;drug benefit management
《保险研究》20231101-《商业保险促进共同富裕提升:机制与效应》(胡宏兵、朱涛)
《保险研究》20231102-《欧盟碳边境调节机制背景下中国低碳转型的风险研究》(林伯强、赵恒松)
《保险研究》20231103-《保险机构经营规范性及其评价指数构建——基于保险纠纷判例大数据》(孙蓉、吴舒祥、万梅雨)
《保险研究》20231104-《河南“7•20”特大雨灾对财产保险公司的冲击:赔付和资产重置》(孟佶贤、李俊宏、康吉嘉、杨晓光)
《保险研究》20231105-《农业保险能否助力农业绿色发展水平提升?——基于13个粮食主产区的评估》(焦雨欣、江生忠、费清)
《保险研究》20231106-《中国企(职)业年金的长期投资目标与“长钱短投”困境的解决之道——基于精算预期收益率的一个统一的分析框架》(孙守纪、费平、张寓)